A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma

IRB/UVA Tracking #
20729
Contact
Kim M Underwood
Contact Email
Contact Phone
1.434.982.3947
Phase
III
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL